454 related articles for article (PubMed ID: 25694537)
21. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.
Beyer-Westendorf J; Förster K; Pannach S; Ebertz F; Gelbricht V; Thieme C; Michalski F; Köhler C; Werth S; Sahin K; Tittl L; Hänsel U; Weiss N
Blood; 2014 Aug; 124(6):955-62. PubMed ID: 24859362
[TBL] [Abstract][Full Text] [Related]
22. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
24. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560
[TBL] [Abstract][Full Text] [Related]
25. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
27. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
[TBL] [Abstract][Full Text] [Related]
28. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
29. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
30. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Cappato R; Ezekowitz MD; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca M; Vardas PE; Kirchhof P; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M; Hohnloser SH;
Eur Heart J; 2014 Dec; 35(47):3346-55. PubMed ID: 25182247
[TBL] [Abstract][Full Text] [Related]
31. Atrial fibrillation and chronic kidney disease: focus on rivaroxaban.
Barrios V; Górriz JL
J Comp Eff Res; 2015 Nov; 4(6):651-64. PubMed ID: 26388302
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
[TBL] [Abstract][Full Text] [Related]
33. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
34. [New Oral Anticoagulants During Catheter Ablation of Atrial Fibrillation. Experience With Rivaroxaban].
Kazakov AI; Yashin SM; Lyan EV; Ayrapetyan AV
Kardiologiia; 2015; 55(8):30-4. PubMed ID: 26761969
[TBL] [Abstract][Full Text] [Related]
35. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
Piccini JP; Garg J; Patel MR; Lokhnygina Y; Goodman SG; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Mahaffey KW; Singer DE; Califf RM; Fox KA;
Eur Heart J; 2014 Jul; 35(28):1873-80. PubMed ID: 24658769
[TBL] [Abstract][Full Text] [Related]
36. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.
De Vriese AS; Caluwé R; Pyfferoen L; De Bacquer D; De Boeck K; Delanote J; De Surgeloose D; Van Hoenacker P; Van Vlem B; Verbeke F
J Am Soc Nephrol; 2020 Jan; 31(1):186-196. PubMed ID: 31704740
[TBL] [Abstract][Full Text] [Related]
37. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
[TBL] [Abstract][Full Text] [Related]
38. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
[TBL] [Abstract][Full Text] [Related]
39. Patterns of atrial fibrillation anticoagulation with rivaroxaban - 7-year follow-up from the Dresden NOAC registry.
Tittl L; Marten S; Naue C; Beyer-Westendorf J
Thromb Res; 2024 Apr; 236():61-67. PubMed ID: 38394987
[TBL] [Abstract][Full Text] [Related]
40. Left atrial thrombus formation after brief interruption of rivaroxaban.
Turner M; Solarz D
Am J Emerg Med; 2016 Jan; 34(1):116.e3-4. PubMed ID: 26081413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
